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Summary
Idiopathic basal ganglia calcification (IBGC) is a neu-
rodegenerative syndrome that is associated with a va-
riety of movement disorders and neurobehavioral and
cognitive manifestations. Despite numerous clinical,
pathological, and biochemical investigations, its etiology
remains unknown. We have identified a multigenera-
tional family with dominantly inherited IBGC and, in
24 members of this family, performed a whole-genome
scan using polymorphic microsatellite markers to iden-
tify the first chromosomal locus for this disorder
(IBGC1). A maximum two-point LOD score of 3.37 was
obtained at marker D14S1014, and a maximum mul-
tipoint LOD score of 4.95 was obtained between
D14S75 and D14S306. The minimal haplotype shared
by affected patients extended over a 17.1-cM region
bounded by D14S70 and D14S66, which is potentially
further narrowed to a 13.3-cM region by a recombi-
nation observed in a patient with probable affected
status. The age at onset appeared to be decreasing by
an average of 120 years with each transmission, which
is consistent with genetic anticipation.
Introduction
Calcification of the basal ganglia has been linked to 130
medical conditions, including a variety of infectious,
metabolic, and genetic syndromes (Moskowitz et al.
1971; Harrington et al. 1981; Lowenthal 1986; Legido
et al. 1988; Fenelon et al. 1993; Etcharry-Bouyx et al.
1995). Why these conditions, most of which are sys-
temic, cause focal calcium deposition in the basal ganglia
is unknown. Calcification of the basal ganglia is also
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observed in ∼0.7% of CT scans as an incidental finding
(Koller et al. 1979; Harrington et al. 1981). These in-
cidental calcifications are usually benign and without
any clearly identifiable etiology, especially in patients
aged 160 years.
In contrast, patients with familial idiopathic basal
ganglia calcification (IBGC [MIM 213600]), which is
synonymous with Fahr disease, typically do not share a
benign prognosis. IBGC is among the few inherited neu-
rologic conditions that can lead to progressive dystonia,
parkinsonism, and neuropsychiatric manifestations
(Konig and Haller 1985; Larsen et al. 1985; Ellie et al.
1989; Manyam et al. 1992; Gasser 1997). The majority
of families with IBGC demonstrate a pattern of inheri-
tance consistent with autosomal dominant transmission,
and most patients with IBGC are symptomatic (Low-
enthal 1986; Ellie et al. 1989). Typically, age at onset
of clinical symptoms is 30–60 years (Konig and Haller
1985; Lowenthal 1986; Ellie et al. 1989; Manyam et al.
1992). The core clinical features of IBGC are dysarthria,
extrapyramidal signs, and ataxia. The clinical and im-
aging abnormalities are restricted to the CNS (Lowen-
thal 1986; Flint and Goldstein 1992). The most common
area of calcification is the globus pallidus. However, ad-
ditional areas of involvement may include the putamen,
caudate, dentate, thalamus, and cerebral white matter.
Calcification also can occur in the cerebellum and in-
ternal capsule. However, even within families, the ex-
pressivity of IBGC is varied. A wide range of clinical
findings, including dystonia, parkinsonism, cognitive
dysfunction, and isolated neuropsychiatric abnormali-
ties, have been observed in different members of the
same family with IBGC (Konig and Haller 1985; Ellie
et al. 1989; Manyam et al. 1992) This intrafamilial het-
erogeneity is similar to that observed in other neuro-
degenerative conditions, such as the spinocerebellar
ataxias or the chromosome 17–linked dementias (Ro-
senberg 1995; Wilhelmsen et al. 1996; Geschwind et al.
1997).
The cognitive abnormalities seen in IBGC parallel
those seen at various stages in other degenerative con-
ditions associated with basal ganglia dysfunction (Konig
1989; Laplane et al. 1989; Cummings 1995). IBGC has
been associated with schizophreniform psychosis, per-
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sonality changes, mood disorders, and frontal-subcor-
tical cognitive dysfunction (Trautner et al. 1988; Laplane
et al. 1989; Rosenberg et al. 1991). A recent neurobe-
havioral study of 18 patients with IBGC revealed that
half met standard clinical criteria for obsessive-compul-
sive disorder, bipolar disorder, or major depressive dis-
order and had significant impairment on tests of frontal-
executive function (Lopez-Villegas et al. 1996).
Numerous investigations have demonstrated that
IBGC is clinically and biochemically distinct from dis-
orders of calcium metabolism and is not related to an
infectious or postinfectious syndrome (Moskowitz et al.
1971; Lowenthal 1986). Several detailed pathologic
studies of IBGC have revealed that the calcium deposits
occur in the extracellular and extravascular space, often
surrounding capillaries (Smeyers-Verbeke et al. 1975;
Duckett et al. 1977; Lowenthal 1986), and are micro-
scopically similar to other physiologic calcifications but
are ectopically located. However, it is not clear whether
the CNS calcification in IBGC is a metastatic deposition,
secondary to local disruption of the blood-brain barrier,
or is due to a disorder in neuronal calcium metabolism.
Thus, despite numerous pathological and biochemical
investigations, the etiology of IBGC remains unknown
(Manyam et al. 1992; Kobari et al. 1997). We have
identified a multigenerational family with apparent dom-
inant transmission of IBGC with multiple generations
available for study. A genomewide searchwas performed
in members of this family to identify the first chromo-
somal locus for this enigmatic neurodegenerative con-
dition, on chromosome 14q (IBGC1).
Patients and Methods
Patient History and Clinical Characterization
This pedigree was identified when a 39-year-old, right-
handed woman (patient IV-51) with a history of symp-
tomatic basal ganglia calcification presented her two
daughters (patients V-83 and V-84) for neurologic eval-
uation of a movement disorder. Dystonia and chorea
were identified in one, whereas the other manifested a
coarse tremor and motor delay. Their mother, patient
IV-51, had initially presented with writing tremor at age
18 years, which progressed to focal dystonia and mild
generalized chorea by her mid-20s. Known disorders of
parathyroid hormone or calcium regulation—Wilson
disease, mitochondrial disease, and organic and amino
acid metabolism—and infectious etiologies were elimi-
nated. After informed consent was obtained with a pro-
tocol approved by the UCLA institutional review board,
structured telephone interviews were conducted over the
course of a year (by D.G. and J.S.). Forty-one family
members and 14 physicians were contacted to confirm
or release medical history data. Seven patients had ob-
tained CT scans. The scans were forwarded to us for
review and confirmed disease status in these seven in-
dividuals. Several other patients were suspected of hav-
ing IBGC on the basis of confirmed diagnosis of a move-
ment disorder or chronic psychiatric illness (Trautner et
al. 1988; Flint and Goldstein 1992; Lopez-Villegas et al.
1996).
To confirm the affection status of patients after the
initial data gathering, 28 subjects underwent a detailed
neurologic examination (performed by D.G. and J.S.).
Among these subjects, 20 (primarily adults) underwent
abbreviated neurobehavioral examination (performed
by D.G.) that focused on areas of frontal-executive dys-
function previously demonstrated to be commonly af-
fected in IBGC. Tests included serial sevens and digit
span (Strub and Black 1985), Trail Making B (Trails B;
Reitan 1958), verbal fluency (FAS; Benton and Hamsher
1978), design fluency (Jones-Gotman and Milner 1977),
a go/no-go task, short-termmemory, and two- and three-
dimensional constructions (Strub and Black 1985; Lezak
1995). Histories were obtained for 87 individuals, 28 of
whom were available for examination. CT scans were
obtained for an additional 23 patients, for a total of 30
patients screened by CT scanning. Twelve patients had
positive CT scan results. The most frequent region of
calcification was the globus pallidus, which was involved
in all CT-positive patients, followed by the thalamus and
dentate nucleus, which were involved in three patients.
Eighteen patients had negative CT scan results; only four
of these patients were 150 years old and could be con-
sidered definitely unaffected (see definition below). Two
of the 18 patients with negative CT scans, both of whom
were !30 years old, are suspected of being affected
(probably-affected status; see below) because of the pres-
ence of at least three findings on neurologic examination
(e.g., abnormalities of ocular pursuit or saccades,
masked facies, primitive reflexes, tremor, markedly ab-
normal tone, or limb dysmetria), combined with poor
performance on frontal-lobe tasks ( ), a history ofn = 1
chronic dysphagia ( ), focal limb or facial dystonian = 1
( ), or psychiatric disease ( ).n = 2 n = 1
The diverse expressivity in this family and the variable
penetrance of clinical symptoms in other families re-
ported in the literature created potential ambiguity as to
some subjects’ disease status.More than 95% of affected
patients reported in the literature develop clear symp-
toms and/or positive CT scans by the age of 50 years,
but some obligate gene carriers prior to this age can be
CT-negative despite being clinically symptomatic (Boller
et al. 1977; Larsen et al. 1985; Ellie et al. 1989). Thus,
patients were divided into four liability classes (Ott
1992; Leube et al. 1996). Patients whose CT scans were
positive were classified as definitely affected. Patients
aged !50 years whose CT scan results were negative or
were not obtained and who had histories of medically
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diagnosed parkinsonian syndrome, tic disorder, schizo-
phreniform or bipolar disorder, persistent dystonia, or
swallowing difficulty, and/or three or more abnormal
features on clinical and neurobehavioral examination,
were classified as probably affected. Asymptomatic sub-
jects aged 150 years whose CT scan results were negative
and children or grandchildren of subjects who remained
unaffected until their death (at age 160 years) were clas-
sified as unaffected. Subjects whose CT scan results were
negative or were not obtained, who had two or more
signs or symptoms observed, and who were at-risk chil-
dren or grandchildren (from generation III or IV, age
!50 years) of definitely or probably affected subjects
were classified as having unknown status.
Molecular Genetic and Analytic Methods
Genotyping.—Informed consent was obtained and
DNA was extracted from peripheral blood lymphocytes
by means of the Puregene kit (Gentra Systems). A whole-
genome scan was conducted by means of the Licor/Re-
search Genetics Map Pairs (Research Genetics; Weber
Set, Version 8a), containing 152 autosomal markers at
an average density of 20 cM. We PCR-amplified the
initial screening set of microsatellite markers using 40
ng of patient DNA and 0.2 pmol of fluorescently labeled
primers (IRD700 at 700nm and IRD800 at 833 nm) in
a reaction mixture containing 2 mM MgCl2, 200 mM
dNTPs, 0.75 U Taq DNA polymerase (Qiagen), and 1
# Qiagen PCR buffer under the following cycling con-
ditions: 95C for 4 min, then 30 cycles of 95C for 45
s and 55C for 45 s, followed by a final extension at
72C for 6 min. M13-tailed microsatellite markers were
used to follow up on regions with initially positive LOD
scores. In this case, IRD-labeled M13 forward (0.8 pmo-
les) or labeled reverse primer was added to the reaction
mixture, and an extension step at 72C for 90 s was
added to follow the 55C annealing step in each cycle.
Samples were electrophoresed in 6% acrylamide/7M
Urea Long Ranger gels (FMC) on a Licor 4200L fluo-
rescent sequencer, analyzed by means of GeneImage IR
version 3.0 software (Licor Biotechnologies), and stored
in the GeneImage IR PB database. Pedigree information
was linked with genotype data by means of the Progeny
database (Genetic Data Systems).
Linkage Analysis.—Two-point linkage analysis was
done with the VITESSE program (O’Connell and Weeks
1995). Marker-allele frequencies were derived from val-
ues published in the Genome Database on the basis of
CEPH-pedigree genotypes. A dominant model of inher-
itance was specified, with a gene frequency of .001. In-
itially, penetrance was set at 95%, and linkage analysis
was done with 11 CT-positive definitely affected patients
and 5 family members patients, to identify regions with
LOD scores 12.0 for follow-up. Multipoint analysis was
done by means of the linkmap routine of the VITESSE
program (O’Connell and Weeks 1995). Marker dis-
tances and order were derived from the Whitehead STS
Map of the Human Genome (release 12; 7/97), compiled
from the most recent Ge´ne´thon (Dib et al. 1996) and
Whitehead RH-mapping data, and are shown alongside
the markers in figure 2
Results
History and examination data suggested that IBGC
was transmitted over four generations in an autosomal
dominant fashion (fig. 1). Twelve subjects had calcifi-
cations evident on CT scan, and, of these subjects, 10
were available for examination. These 10 subjects all
exhibited evidence of a movement disorder either on
examination or by history (table 1). The average age at
onset of clinical symptoms was 37 years (range 5–65
years) and appeared to be decreasing in successive gen-
erations. Clinical presentations included dysphagia, fo-
cal dystonia, tremor, parkinsonism, and psychosis. Four
subjects exhibited focal upper- or lower-limb dystonia
on examination, whereas three additional subjects had
a progressive history of writer’s cramp or jaw dystonia.
Two subjects aged 160 years displayed prominent par-
kinsonism, whereas several younger subjects exhibited
parkinsonian features such as a resting tremor, lead-pipe
rigidity, or masked facies. One patient also had a long
history of schizophreniform psychosis. An additional pa-
tient (IV-27) with calcifications visible on CT scan is
reported by his primary-care physician to be neurolog-
ically normal, although he has not been examined by a
neurologist and is considered affected. He has a long
history of poor concentration, bilateral lower-extremity
cramps, and rapid brief jerking movements, as well as
unilateral globus pallidus calcification visible on CT
scan. He brings the total number of definite affecteds
participating in this study to 11. The remaining subject
with a positive CT scan has not been available for DNA
studies.
No patient with IBGC performed poorly on tests of
memory or visuospatial construction, but all definitely
affected adults who were tested ( ) failed at leastn = 8
one among the Trails B, verbal fluency, or design fluency
tests, indicating frontal-executive dysfunction (Cum-
mings 1995). At least one subject (IV-84) with positive
CT scans has a history of several previously negative CT
scans obtained after the onset of clinical disease. This is
consistent with reports of obligate gene carriers with
significant neurologic or psychiatric disease and negative
CT scans (Larsen et al. 1985). In addition to two spouses
(IV-52 and IV-33), four at-risk asymptomatic patients
age 150 years had negative CT scans (IV-15, IV-17, IV-
18, and IV-40) and were considered definitely unaf-
Figure 1 Pedigree of family with dominantly inherited IBGC. IBGC has been transmitted over at least three generations in this family, with relatively high penetrance and variable expressivity.
The asterisks identify individuals from whom DNA was available and who were used in linkage analysis. Because of the pedigree’s size, not all family members are shown. Other branches of this
family exist, but they have not been available for study and have not yet been completely ascertained.
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Table 1






(years) Principal Clinical Features
III-15a 73 60 Parkinsonism, dystonia
III-18 76 70 Parkinsonism
III-26 70 58 Dysphagia, parkinsonism
IV-7 50 23 Psychosis, parkinsonism
IV-25 52 37 Focal dystonia, tremor, panic attacks
IV-27 58 * Cramps, jerking
IV-32 43 36 Ataxia, tremor
IV-45 46 37 Focal dystonia, dysphagia
IV-49 41 40 Parkinsonism
IV-51 40 18 Writing tremor, focal dystonia, chorea
V-4 38 * Focal dystonia, cramps
V-74b 29 12 Focal dystonia, tremor
V-75b 28 13 Tremor, dysphagia
V-83 10 6 Dysphagia, focal dystonia
V-84 9 5 Tremor, dystonia
*Age at onset uncertain (10–20 years, by history).
a Positive CT scan, known clinical history, but not examined
(deceased).
b Probably affected (negative CT scan, age !30 years).
fected. However, one of these patients (IV-40) was not
available for use in the initial analysis.
Linkage Analysis
An initial whole-genome scan with 152 autosomal mi-
crosatellite markers at an average density of 20 cM was
used in a subset of available individuals in whom af-
fected status could be definitely ascertained ( , 11n = 16
affected and 5 unaffected). Simulation of linkage in this
subset of individuals, using SLINK (Ott 1989), led to a
maximum estimated LOD score of 3.2 at recombination
fraction (v) 0 after 200 replications. Two regions with
LOD scores 12 were identified. One of these loci on
chromosome 8 (D8S1132) was eliminated by genotyping
closely flanking markers that yielded LOD scores below
2.0 at both markers. Both markers were within 2–3
cM of D8S1132, demonstrating that the initial associ-
ation at this marker was a random association and that
this chromosomal region was unlinked to the disease.
The second locus on chromosome 14q (D14S306)
yielded a LOD score of 3.1 ( ). Analysis of sur-v = 0
rounding Weber set 8a markers D14S1280, ∼25 cM cen-
tromeric to D14S306, and D14S592, ∼20 cM telomeric
to D14S306, gave LOD scores of 3.4 and 3.7, de-
fining a 46-cM interval within 14q likely to contain the
IBGC locus.
Multipoint Linkage and Haplotype Analyses
An additional 12 markers in this region (chromosome
14) were typed to define more narrowly the disease hap-
lotype. None of the markers surrounding this locus were
fully informative in this family and yielded lower, but
still positive, LOD scores. The minimum haplotype
shared by all affected patients spanned a 17.1-cM region
bounded by D14S70 andD14S66 (fig. 2). This haplotype
was treated as a single allele, to increase the informa-
tiveness of the markers in two-point linkage analysis
(Ottman et al. 1995). This yielded a LOD score of 3.4
in this subset of 16 patients with certain disease status.
Since a value of 3.3 is significant at the levelP ! .00005
in two-point analysis (Lander and Kruglyak 1995) and
a LOD score 13.0 is often considered sufficient, these
results provide significant evidence of linkage (Ott
1992). Multipoint linkage analysis using this initial sub-
set of 16 clearly defined patients was also conducted,
demonstrating a maximum LOD score of 3.7 between
D14S75 and D14S306 (fig. 3). The 3-LOD-score support
interval was between markers D14S1040 and D14S989,
conservatively defining a broader 20-cM region most
likely to contain the disease locus, which largely coin-
cided with the affected haplotype.
To take full advantage of the pedigree, eight remaining
individuals for whom DNA was available and whose
disease status could be determined from clinical and im-
aging data were genotyped and added to the analysis.
One of these subjects was aged 150 years and clinically
asymptomatic, with negative CT scan results, and thus
was considered unaffected. Five subjects were aged !50
years, and, although clinically asymptomatic (on the ba-
sis of neurologic examinations and negative CT scan
results), they could have been carriers because of their
age. In this case, penetrance was set at 75% for those
subjects aged !50 years and at 95% for those aged 150
years, which is consistent with previous reports in the
literature (Boller et al. 1977; Okada et al. 1981; Francis
and Freeman 1984; Larsen et al. 1985; Ellie et al. 1989;
Manyam et al. 1992). Two subjects were classified as
probably affected, since they were symptomatic by his-
tory and had numerous findings on neurologic exami-
nation but had negative CT scans and were aged !40
years (liability class of 75% affected status, 25% phe-
nocopy rate). Thus, a total of 13 definitely or probably
affected subjects and 11 unaffected subjects were gen-
otyped with a set of densely spaced markers over the
chromosome 14q11-21 region. Probably affected subject
V-75 (who had symptoms and a positive neurologic ex-
amination but negative CT scan results at age 25 years)
showed a recombination distal to D14S259, partially
narrowing the disease-associated haplotype to a 13.3-
cM region (fig. 2). Two-point linkage analysis using all
24 subjects and the assumptions specified above yielded
a maximum single-point LOD score of ∼3.3 at
D14S1040 (3.37), D14S75 (3.3), and D14S306 (3.27),
all spanning a 1.2-cM region (fig. 2). Multipoint linkage
analysis yielded a maximum LOD score of 4.95 between
markers D14S75 and D14S306 and established a 3-
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Figure 2 Defining an affected haplotype. Marker names are listed to the far left, next to the map positions defined by Ge´ne´thon and
Whitehead mapping data. The marker distances are in centimorgans relative to the telomere (0 cM). Depicted haplotypes are from those patients
with definitely affected status, except V-75 (probably affected, labeled with *) and IV-18 (unaffected, labeled with **). The arrows highlight
recombinants important in defining the minimal haplotype shared by affected patients. The narrowest shared region is bordered by D14S70
and D14S989, narrowed by a recombination in probably affected subject V-75 and in unaffected subject IV-18. A slightly broader shared 17-
cM region, bounded by D14S70 and D14S66, is inherited with IBGC if only the subset of affected individuals with definite CT-scan evidence
of disease is considered.
Figure 3 The composite LOD-score curve derived from multi-
point analysis. Two models are shown. The dotted line shows the
multipoint analysis derived from sequential four-point analysis with
the VITESSE algorithm (O’Connell and Weeks 1995), obtained with
the most conservative initial subset of 16 family members (simple
model). The solid bold line depicts the multipoint results obtained from
analysis of all 24 available subjects (full model). Peak multipoint LOD
scores were found in both models between markers D14S75 and
D14S306.
LOD-score support interval to the 20 cM region between
markers D14S1040 and D14S989 (fig. 3), a region over-
lapping with the minimum affected haplotype but ex-
tending 3 cM beyond its centromeric border.
Anticipation
The age at onset of clinical symptoms appeared to be
decreasing with successive transmissions. For statistical
analysis, only those subjects with CT evidence of basal
ganglia calcification who were descended from the ear-
liest definitely affected patients (i.e., III-15, III-18, and
III-26) and in whom reasonable age-at-onset informa-
tion was available were considered (IV-25, IV-51, IV-49,
IV-45, IV-32, V-83, and V-84). This demonstrates an
average decrease in age at onset of 20 years with each
transmission (range 12–40 years), significantly different
from random transmission ( , one-tailed t test).P ! .01
No offspring had a later age at onset than his or her
parents, even among those in whom age at onset could
not be defined as precisely (e.g., IV-27 and IV-7). This
decreasing age at onset in successive generations is con-
sistent with the phenomenon of genetic anticipation,
which in many cases has been associated with triplet
repeat expansions (Rosenberg 1996).
Discussion
This study establishes the first chromosomal locus,
IBGC1, for dominantly inherited IBGC (Fahr disease).
A large family with three generations available that was
informative for linkage analysis, using a subset of 16
individuals with the most certain disease status, yielded
a two-point LOD score of 3.1 at D14S306 and a mul-
tipoint LOD score of 3.7 near D14S306. When the af-
fected haplotype was treated as one allele and only the
minimal group of 16 subjects with the most certain dis-
ease status was used, the LOD score was 3.4. These
results demonstrate significant linkage of IBGC to this
locus.
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Typing all patients who were evaluated allowed us to
more fully use all genotypic and phenotypic data col-
lected and helped to narrow the disease-associated hap-
lotype to a 13.3-cM region on chromosome 14 (between
14q11.2 and 14q21.3) with a single-point LOD score
of 3.37 and a peak multipoint LOD score of 4.95 be-
tween D14S75 and D14S306. A narrower (6.2-cM) re-
gion between markers D14S70 and D14S288 yielded a
1-LOD-unit support interval with bimodal peaks. A 3-
LOD-unit support interval for the disease locus is con-
sidered more stringent. The 3-LOD-unit support interval
extends slightly beyond the region defined by haplotype
analysis because the disease allele in the marker at the
border happens to be a common allele. Multipoint anal-
ysis thus interprets this marker as ambiguous, extending
the support interval to the next adjacent marker, ∼3 cM
away. The 3-LOD-unit support interval in this case was
largely coincident with the region of minimal affected
haplotype defined by recombinants, which is 13.3 cM
in length. This narrower haplotype was defined with
several younger patients who were considered affected
on the basis of neurologic examination, one of whom
had a recombination that helped to potentially narrow
the locus to this area. A more conservative approach is
consideration of only those subjects more strictly defined
as affected because of their positive CT scan results; this
approach defines a slightly larger, 17.1-cM interval.
More subjects with affected status defined by positive
CT scan results will be needed to narrow the locus fur-
ther and more definitely.
The large IBGC family studied here demonstrates the
full range of symptoms and examination findings that
have been described in many smaller families, including
dystonia, parkinsonism, chorea, frontal-executive dys-
function or dementia, and psychiatric conditions (Konig
and Haller 1985; Larsen et al. 1985; Ellie et al. 1989;
Manyam et al. 1992). A more detailed description of
the clinical and neuroimaging findings of this family is
in preparation (J. Stern and D. Geschwind). Whether
pedigrees described elsewhere with dominantly inherited
basal ganglia calcification and a variety of movement
disorders show linkage to this 14q region will be im-
portant to determine, both to narrow the disease locus,
and to demonstrate genetic homogeneity or heteroge-
neity of this condition.
Currently, seven loci for different forms of dystonia
have been mapped in humans, and three genes have been
identified (Nygaard et al. 1993; Knappskog et al. 1995;
Ludecke et al. 1995; Ozelius et al. 1997). None of these
conditions are known to be associated with IBGC. One
of these loci, which causes dopa-responsive dystonia, lies
on chromosome 14q (Nygaard et al. 1993; Ichinose and
Nagatsu 1997), and causal point mutations within the
gene, GTP cyclohydrolase I, have been identified (Ichi-
nose et al. 1994). This gene lies between markers
D14S989 and D14S66, which could be considered
within the affected chromosomal region if one is con-
servative and considers only those patients with themost
certain disease status (i.e., affected patients with CT-scan
evidence of IBGC). In V-75, a probably affected subject,
a recombination occurred proximal to D14S989, poten-
tially narrowing the likely disease-critical region proxi-
mal to this marker. However, because mutations in this
gene are a known cause of dystonia, we have sequenced
all 6 exons of GTP cyclohydrase I and short sections of
neighboring intronic regions in several affected and un-
affected members of this family and have uncovered no
mutations thus far.
The affected haplotype spans a region that is unwieldy
for classic positional cloning approaches but is covered
by two Whitehead YAC contigs—wc14.0 and 14.1, se-
lected regions of which have been sequenced. Numerous
candidate genes are in this region, and 1100 expressed-
sequence tags and known genes are currently known to
reside in this interval. Some interesting current candi-
dates include a proteosome subunit (PSMA6), the so-
matostatin receptor (SSTR1), the kinesin receptor
(KTN1), paraplegin (a putative mitochondrial ATPase,
deleted in hereditary spastic paraplegia), and the A ki-
nase anchor protein (AKAP100). Although this is a large
region, the presence of what appears to be striking ge-
netic anticipation suggests that a trinucleotide repeat ex-
pansion could cause this condition, which could simplify
the identification of the causal mutation. The availability
of the two YAC contigs spanning this region will facil-
itate this process. Although the detection of anticipation
is subject to many sources of bias, including incomplete
ascertainment, close to the expected 50% of the at-risk
offspring of generations IV (46%) and V (38%) are
themselves affected. This suggests that bias introduced
by the ascertainment of only the youngest affecteds in
recent generations, leaving out a number of other car-
riers who will be affected at later ages, is unlikely to be
a significant problem. In addition, several of these off-
spring (e.g., IV-45, IV-32, V-83, and V-84) showed clin-
ical signs earlier than their parents or grandparents did,
thus decreasing bias introduced from increased vigilance
leading to earlier detection. However, anticipation can
only be suspected on the basis of statistical grounds and
not assumed, which leaves ascertainment of additional
family members or other pedigrees as the most certain
approach to narrowing the disease locus to permit more
efficient positional cloning approaches. Identification of
the gene underlying this condition will be an important
addition to our understanding of the biological path-
ways that can lead to basal ganglia dysfunction and
neurodegeneration.
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